Latest Intellectual Property News

Cynata Therapeutics is on the cusp of releasing critical data from its Phase 2 aGvHD and Phase 3 osteoarthritis trials in Q2 2026, while managing a tight cash runway and preparing for a capital raising.

TrivarX has made significant strides in preparing its Stabl-Im stable isotope imaging platform for Phase 1 clinical trials, backed by strengthened leadership and a solid cash reserve of $2.91 million.

Latrobe Magnesium has achieved continuous production of high-grade Magnesium Oxide from brown coal ash and secured a US$2 million prepayment from its US offtake partner, setting the stage for magnesium metal production in the second half of 2026.

Beonic Limited’s Q3 FY26 results highlight a tripling of EBITDA margin to 15.8%, driven by operational leverage and gross margin expansion, while the Moroccan Airports rollout stays on track for full delivery by June 2026.

Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.

Li-S Energy secured $1.9 million from ARENA to fund a feasibility study scaling production to 1 GWh, expanded its Battery Testing Centre, and delivered its first drone battery pack under a government program, while progressing key transport certifications.

AdAlta has launched its East-to-West cellular immunotherapy strategy through a co-development deal for CAR-T therapy BZDS1901, showing promising complete tumour clearance in mesothelioma patients and transferring manufacturing to Australia to boost scalability.

Appen Limited’s Q1 FY26 revenue rose 9% year-on-year to $54.8 million, driven by an 88% surge in its China business. Despite a 37% drop in the Global segment due to seasonality, the company reaffirmed full-year guidance and highlighted expanding AI operational efficiencies.

T&G Global is moving to sell its New Zealand fresh produce and Pacific Island businesses as part of a strategic pivot to concentrate on its premium Apples and VentureFruit platforms. The divestments, pending contract finalisation, mark a significant reshaping of the company’s portfolio amid shareholder shifts.

Anatara Lifesciences delivered ambiguous mechanism of action results for its Anti-Obesity Project while reporting statistically significant weight management effects from compound AOC. The company plans a limited Phase 1 study but may delay it amid ongoing strategic discussions, with cash reserves tightening to $0.7 million.

Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.

Zeotech pushed forward its AusPozz™ metakaolin commercialisation with extended and new MOUs, progressed key Toondoon project approvals amid rising contractor costs, and launched live methane control trials.